Treating diabetes – benefit your influence by finding new R&D trends and sales prospects Discover the future of antidiabetic medicines. For those treatments, you will receive diabetes market size and revenue projections. You will learn the future potential by exploring research and development pipelines. And you will be able to assess results, trends, technologies, therapies and future business opportunities.
Visiongain’s updated report forecasts those revenues to 2025 at overall world market, submarket, product and national level. You can stay ahead with clear market data for treating human diabetes, finding commercial outlooks to benefit your research, analysis and authority.
See what’s possible for treating diabetes mellitus. Read on, then, to explore treatment of those metabolic diseases, also finding those medicines’ predicted revenue.
Forecasts to 2025 and other analyses explain and predict the diabetes treatment market Why miss crucial data that you need? Why struggle to find information? Instead our report gives you revenue forecasts to 2025, also with recent results, growth rates, market shares and discussions.
Our study also shows 90 tables, 91 charts and two interviews. Our work’s purpose is to predict that industry’s future, helping your research, analyses and decisions. See how you can benefit your reputation for commercial insight, also helping your influence.
Diabetes therapies hold some of the strongest prospects for pharmaceutical companies. See why and what sales are possible, finding where money and growth opportunities exist.
The following sections show how our new investigation benefits your work.
Forecasting of the world diabetes drugs market and its segments – what does the future hold? What are the secrets of the industry's progress? Where’s it heading? Discover in our report overall world revenue prediction to 2025 for antidiabetic pharmaceuticals, with discussions.
Also find individual revenue forecasts to 2025 for nine therapeutic submarkets at world level: • Human insulins and analogues • Dipeptidyl peptidase-4 inhibitors (DPP-4) • Biguanides • Glucagon-like peptide-1 receptor agonists (GLP-1) • Sulfonylureas.
And these treatment categories: • Thiazolidinediones • Alpha-glucosidase inhibitors • Meglitinides • Sodium-glucose co-transporter-2 inhibitors (SGLT2) • Other agents (grouped).
You can assess the outlook for revenue expansion, learning where you can profit. Find the diabetes market size from 2015-2025. You can investigate the competition and rising sales. And you will examine technological, clinical and commercial possibilities.
Also you will find top medicines’ revenue potentials.
Predictions of leading products’ sales – see what’s possible, and where you can gain How will individual drugs for elevated blood sugar perform to 2025 at world level? Our study forecasts revenues of 31 leading products. Assess top brands, including these agents: • Lantus • Januvia • NovoLog and NovoMix • Levemir • Humalog • Victoza • Janumet • Humulin.
There you will find drugs and the years with highest predicted sales. You can also examine competitors. So discover what’s happening for lowering blood glucose and controlling its level, understanding challenges, trends, competition and opportunities for revenue expansion.
Our work also gives geographical sales predictions.
National markets – what is the outlook for treatment demand and revenues? In developed and developing countries, many opportunities for producers and sellers of diabetes-treating medicines will occur from 2015 to 2025. See where, how and what’s possible.
Our analyses show you individual revenue forecasts to 2025 for 11 national markets: • United States (US) • Japan • EU leaders – Germany, France, the UK, Italy and Spain (EU5) • BRIC nations – Brazil, Russia, India and China.
There you can explore the market progress, needs and opportunities. What events will change that market and the outlook for payers and patients? Our work shows you, discussing the trends and demands.
Events affecting developers, producers and sellers of those metabolic treatments Our report also explains issues, forces and events affecting the antidiabetics industry and market from 2015, including these influences: • Drug approvals and R&D in human insulins and analogues, DPP-4 inhibition, GLP-1 therapies, sodium glucose co-transporter mechanisms and other candidates • Governmental investment and collaboration between pharmaceutical companies • Combination therapies for type 2 diabetes • Competition from biosimilars and generic drugs – approvals and product launches.
And these issues are also assessed, among others: • Disease incidence and prevalence • Risk factors – obesity and pre-diabetes, related metabolic conditions • Drug delivery – technologies for introducing insulin and oral drugs • New classes of antidiabetic medications and regulatory challenges • Type 1 diabetes vaccine – new treatment approaches, including disease prevention.
Diabetes management forms a leading use for biological drugs, now dominant in the pharmaceuticals industry. There you can investigate what stimulates and restrains that biopharma, affecting its results. Also you will see the prospects for small-molecule therapies.
Analysis of firms and potential for rising sales – what overall revenues are possible? What happens next? Our study predicts the world market will rise to $72.6bn in 2019, with high, expanding revenues from 2015 to 2025. Discover what’s possible.
Our analysis covers organisations shaping that industry: • Novo Nordisk • Eli Lilly • Novartis • AstraZeneca • Merck & Co.
We also investigate these leading companies, among other firms, including specialists in metabolic disorders: • Boehringer Ingelheim • Takeda • Sanofi • Bayer • Pfizer.
And you will gain interviews with two other authorities on diabetes treatments. Our survey explores issues affecting that healthcare industry’s present and future.
From 2015, new treatments and demands from patients, doctors and payers encourage investments, medical advances and higher revenues from those medications.
Ways Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025 helps In particular, our new investigation gives this knowledge to benefit your work: • Antidiabetic drug revenues to 2025 at overall world level, for 9 therapeutic submarkets and 31 products – assess outlooks for production, marketing and sales • Forecasts to 2025 for 11 national markets in the Americas, Europe and Asia – investigate developed and developing countries for demand and revenue potentials • Prospects for established competitors, rising companies and new entrants – explore portfolios, opinions, results, strategies, technologies and outlooks for success • Review of R&D pipelines – examine progress in research and development, finding technological and medical prospects • Analysis of what stimulates and restrains that industry and market – gauge challenges and strengths, helping you compete, gain advantages and succeed.
Our new study, produced in-house by our UK-based analysts, helps your knowledge and authority.
Information found nowhere else, helping your searches, analyses and plans – and your success And what is our methodology? We get the most from data, interpreting its meaning for business now and for the future.
We digest publications and survey authorities, saving you time and difficulty, helping your planning and decisions. You will hear what’s happening, getting a feel for companies’ prospects.
And our study gives independent analysis. There you will receive competitive intelligence found only in our report, finding where progress, money and opportunities exist.
Our work assesses diabetes medicines, their producers and commercial outlooks in detail. That way you find potential gains, discovering opportunities to harness, as well as benefiting your influence.
Trying our investigation now lets you see opportunities and revenue predictions So with our survey you’re less likely to fall behind in knowledge or miss opportunity. You will find how to save time and effort, also benefiting your insight, authority and your company’s prospects.
Our new analysis helps professionals like you assess the market for diabetes treatments. You can explore the trends, discussions and sales forecasting. Avoid missing out in knowledge. Benefit by getting our report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview 1.1 Introduction to that Industry and Market 1.2 Main Report Findings 1.3 This Study Provides the Following Knowledge 1.4 Why You Should Read This Report 1.5 How This Report Delivers 1.6 Main Questions Answered 1.7 Who is This Study For? 1.8 Research and Analysis Methods 1.9 Frequently Asked Questions (FAQ) 1.10 Associated Visiongain Reports 1.11 About Visiongain
2. Global Diabetes Drug Market: Introduction 2.1 World Diabetes Drugs Market Segmentation 2.2 What is Diabetes? 2.3 How is Diabetes Classified 2.4 Risk Factors, Disease Symptoms and Complications 2.5 Criteria for the Diagnosis of Diabetes 2.6 World and Regional Diabetes Incidence and Prevalence 2.7 The Economic Burden of Diabetes 2.8 Unmet Need 2.9 Leading Classes of Diabetic Medications 2.9.1 Type 1 Medication 2.9.1.1 Insulin 2.9.1.2 Surgical Options 2.9.2 Type 2 Medication 2.9.2.1 Alpha-glucosidase Inhibitors 2.9.2.2 Biguanides 2.9.2.3 Dipeptidyl Peptidase-4 (DPP-4) Inhibitors 2.9.2.4 Sodium-Glucose Co-Transporter 2 (SGLT2) 2.9.2.5 Thiazolidinediones 2.9.2.6 Sulfonylureas 2.9.2.7 Meglitinides 2.9.2.8 Other Injectable Medications 2.9.2.9 Combination Drug Therapies for Type 2 Diabetes
3. The World Diabetes Drugs Market, 2015-2025 3.1 The World Diabetes Drug Market, 2014 3.1.1 Diabetes Treatment Market by Drug Class, 2014 3.1.2 Top Selling Diabetes Drugs, 2014 3.1.3 Generic Anti Diabetes Drugs, 2014 3.1.4 Top 10 Diabetes Drug Producers, 2014 3.2 World Diabetes Drugs Market: Revenue Forecast, 2015-2025
4. Human Insulin and Analogues Market, 2015-2025 4.1 Insulin and Insulin Analogues Drugs, 2014 4.2 Insulin and Insulin Analogues: Revenue Forecast, 2015-2025 4.3 Insulin and Insulin Analogues: Market Trends, 2015-2025 4.3.1 Will the Top 3 Insulin Producers Sustain Their Market Dominance? 4.3.2 New Opportunities for Biosimilar Insulin: Is the Era of Biosimilar Insulin Coming? 4.4 Lantus (Insulin Aspart, Novo Nordisk): Revenue Forecast, 2015-2025 4.5 NovoLog (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2015-2025 4.6 Humalog (Insulin Lispro; Eli Lilly): Revenue Forecast, 2015-2025 4.7 Levemir (Insulin Detemir; Novo Nordisk): Revenue Forecast, 2015-2025 4.8 Human Insulins (Novo Nordisk): Revenue Forecast, 2015-2025 4.9 NovoMix (Insulin Aspart; Novo Nordisk): Revenue Forecast, 2015-2025 4.10 Humulin (Insulin Isophane; Eli Lilly): Revenue Forecast, 2015-2025
13. National Markets for Diabetes Drugs, 2015-2025 13.1 Leading National Markets for Diabetes Drugs, 2014 13.2 Leading National Diabetes Drugs Market: Revenue Forecast, 2015-2025 13.3 The US to Sustain its Market Leadership: Revenue Forecast 2015-2025 13.3.1 High Diabetes Prevalence within a Complex Healthcare System 13.4 The Japanese Market, Revenue Forecast 2015-2025 13.4.1 Increased Governmental Investment Will Drive Market Growth 13.4.2 Sanofi and Takeda Collaborate to Fight Diabetes in Japan 13.4.3 Novel Treatment Options in Japan 13.5 EU5 (Germany, France, UK, Italy, Spain) Market for Diabetes Drugs, 2014 13.5.1 The EU5 (Germany, France, UK, Italy, Spain) Market: Revenue Forecasts, 2015-2025 13.5.1.1 Germany: Disease Treatment Measures Require Improvement - Revenue Forecast, 2015-2025 13.5.1.2 Great Standard of Care and Regulatory Reforms in France - Revenue Forecast 2015-2025 13.5.1.3 Austerity Measures in Spain Discourage Companies - Revenue Forecast 2015-2025 13.5.1.4 UK: High Burden of Diabetes Costs on the UK NHS 13.5.1.5 Italy: Stable Market with Good Standards of Care - Revenue Forecast, 2015-2025 13.6 China: The World’s Largest Diabetic Population - Revenue Forecast, 2015-2025 13.6.1 Presence of Multinational Companies and the Power of Buyers 13.6.2 Disparity in Regional Health Spending 13.6.3 Multi-Billion Dollar Investment to Improve Healthcare 13.7 The Indian Market: Revenue Forecast, 2015-2025. 13.7.1 Focus on the Rural Population 13.8 Introduction of Novel Therapies in the Russian Federation - Revenue Forecast, 2015-2025 13.8.1 High Out of Pocket Costs Reduce Compliance 13.9 Brazil: Improved Access to Care in Rural Areas - Revenue Forecast, 2015-2025 13.9.1 Localized Insulin Production in Brazil 13.9.2 Diabetes Awareness Initiatives will Increase Market Potential
14. Diabetes Drug Market R&D Pipeline, 2015 14.1 New Diabetes Drugs Approvals and Leading Companies’ Developments, 2015 14.1.1 Novo Nordisk 14.1.2 Eli Lilly & Boehringer Ingelheim 14.1.3 AstraZeneca 14.2 Human Insulins and Analogues: New Approvals 14.2.1 Insulin Glargine (LY2963016 Eli Lilly and Boehringer Ingelheim): US Approval Delay May Trigger High Revenues 14.2.2 Insulin Glargine (U300 Sanofi): Will it Replace Lantus? 14.2.3 Afrezza (Sanofi and MannKind): The First Inhaled Insulin. Will it Reach $1bn Sales? 14.3 Human Insulins and Analogues: Pipeline Developments, 2015 14.3.1 Tresiba (Novo Nordisk): Opportunity Revival 14.3.2 Basal Insulin Peglispro-BIL (Eli Lilly): Holding Promise – What Will More Testing Bring? 14.3.3 MK-1293 (Merck & Co. and Biogen Idec): Another Biosimilar of Lantus on the Way 14.3.4 OG217SC (Novo Nordisk) 14.4 DPP-4 Inhibitors: Pipeline Developments 14.4.1 Zafatek (Trelagliptin Succinate; Takeda and Furiex) Pharmaceuticals): Approved in Japan 14.4.2 Omarigliptin (MK-3102; Merck & Co.) 14.4.3 ARI-2243 (Arisaph) 14.5 GLP-1: New Approvals and Pipeline, 2015 14.5.1 Trulicity (Dulaglutide; Eli Lilly): Does it have the Potential to Reach Blockbuster Status? 14.5.2 Tanzeum (Albiglutide; GSK) 14.5.3 Semaglutide (NN9535; Novo Nordisk) 14.5.4 Xultophy (formerly IDegLira; Novo Nordisk) 14.5.5 ITC650 (Intarcia Therapeutics) 14.6 Sodium Glucose Co-Transporter 2: Pipeline Developments, 2015 14.6.1 Suglat (Ipragliflozin; Astellas Pharma/Kotobuki) 14.6.2 Apleway (Tofogliflozin; Sanofi/Takeda) 14.6.3 Lusefi (Luseogliflozin; Taisho Pharmaceutical) 14.7 Other Anti Diabetes Drugs: Pipeline Developments, 2015 14.7.1 DM199 (DiaMedica) 14.7.2 DiaPep277 (Andromeda Biotech) 14.7.3 Glucokinase Activators 14.7.4 ZYGK1 (Zydus Cadila Healthcare) 14.7.5 LY2608204 (Eli Lilly and Yabao Pharmaceutical Inc.)
15. Diabetes Drugs: World Industry, Market and R&D Analysis, 2015-2025 15.1 SWOT Analysis of the Diabetes Drug Market, 2015-2025 15.2 Strengths 15.2.1 Promising Research and Development 15.2.2 Secondary Indications 15.2.3 Biological Drugs are Tougher to Copy and Offer Variety 15.2.4 Market Competition 15.3 Weaknesses 15.3.1 Lack of Disease Awareness 15.3.2 Tougher Reimbursement Rules 15.3.3 Increased Risk of Cardiovascular Complications 15.3.4 Rising Cost of Drug Development 15.4 Opportunities 15.4.1 Rising Disease Prevalence 15.4.2 Emerging National Markets Hold Great Potential 15.4.3 Novel Insulin Delivery Methods 15.4.4 New Classes of Anti Diabetes Drugs 15.5 Threats 15.5.1 Type 1 Diabetes Vaccine 15.5.2 Increased Popularity of Other Therapies 15.5.3 Generic Drugs: Patent Expiries and Rising Competition 15.5.4 Regulatory Barriers – Challenges Getting Drug Approval 15.6 STEP Analysis of the World Diabetes Drugs Market, 2015-2025 15.6.1 Social Developments 15.6.2 Technological Advances 15.6.3 Economic Factors 15.6.4 Political Issues
16. Research Interviews 16.1 Interview with an Academic Involved in Diabetes R&D 16.1.1 The Insulin Drug Market 16.1.2 Novel Delivery Technologies 16.1.3 Future Developments and Market Prospects 16.2 Interview with James Anderson, Generex Biotechnology Corporation 16.2.1 The Current Diabetes Drug Market 16.2.2 Generex’s Oral-lyn™ Product and Buccal Drug Delivery
17. Conclusions from the Research and Analysis 17.1 The Diabetes Market – Trends Shaping Those Treatments 17.2 Outlook of the Worlds Diabetes Drug Industry, 2015-2025 17.2.1 Insulin Will Continue to Dominate the Market 17.3 Regional Outlooks for That Market, 2015-2025 17.4 Future Opportunities
List of Tables Table 1.1 Leading National Diabetes Drugs Market Forecast, 2015-2025 ($bn, AGR %), 2014-2025 Table 1.2 Foreign Currency Exchange Rates Utilised: Exchange Rate to $USD, 2014 Table 2.1 Types of Injectable Insulin, 2015 Table 2.2 Oral Drug Classes for Type 2 Diabetes, 2015 Table 2.3 Other Injectable Drugs for Type 2 Diabetes, 2015 Table 2.4 Combination Drug Therapies for Type 2 Diabetes, 2015 Table 3.1 World Diabetes Drugs Market: Revenue ($m) and Market Share (%) by Type of Medication, 2014 Table 3.2 World Diabetes Drugs Market: Sales ($m) and Market Share (%) by Drug Class, 2014 Table 3.3 Top 10 Diabetes Drugs Sales ($m), 2014 Table 3.4 Top 3 Human Insulin Producers: Sales ($m), 2014 Table 3.5 Top 10 Diabetes Drugs Producers: Sales ($m), 2014 Table 3.6 World Diabetes Drugs Market: Revenue Forecast ($bn) by Drug Class, 2014-2019 Table 3.7 World Diabetes Drugs Market: Revenue Forecasts ($bn) by Drug Class, 2020-2025 Table 4.1 Human Insulins and Analogues: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014 Table 4.2 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019 Table 4.3 Human Insulins and Analogues: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025 Table 4.4 Top 3 Human Insulin Producers: Sales ($m), 2014 Table 4.5 Lantus: Drug Revenue Forecast ($bn), 2014-2025 Table 4.6 NovoLog: Drug Revenue Forecast ($bn), 2014-2025 Table 4.7 Humalog: Drug Revenue Forecast ($bn), 2014-2025 Table 4.8 Levemir: Revenue Forecast ($bn), 2014-2025 Table 4.9 Human Insulins Novo Nordisk: Revenue Forecast ($bn), 2014-2025 Table 4.10 NovoMix: Revenue Forecast ($bn), 2014-2025 Table 4.11 Humulin: Revenue Forecast ($bn), 2014-2025 Table 5.1 DPP-4 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014 Table 5.2 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019 Table 5.3 DPP-4 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025 Table 5.4 Januvia: Revenue Forecast ($bn), 2014-2025 Table 5.5 Janumet: Revenue Forecast ($bn), 2014-2025 Table 5.6 Galvus: Revenue Forecast ($bn), 2014-2025 Table 5.7 Onglyza: Revenue Forecast ($bn), 2014-2025 Table 5.8 Nesina: Revenue Forecast ($bn), 2014-2025 Table 5.9 Tradjenta: Revenue Forecast ($bn), 2014-2025 Table 6.1 Sulfonylureas: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014 Table 6.2 Sulfonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019 Table 6.3 Sulfonylureas: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025 Table 6.4 Diamicron: Revenue Forecast ($bn), 2014-2025 Table 6.5 Amaryl: Revenue Forecast ($bn), 2014-2025 Table 6.6 Glucotrol: Revenue Forecast ($bn), 2014-2025 Table 7.1 GLP-1: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014 Table 7.2 GLP-1 Receptor Agonists: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019 Table 7.3 GLP-1 Receptor Agonists: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025 Table 7.4 Victoza: Revenue Forecast ($bn), 2014-2025 Table 7.5 Byetta: Revenue Forecast ($bn), 2014-2025 Table 7.6 Bydureon: Revenue Forecast ($bn), 2014-2025 Table 8.1 Alpha-glucosidase Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014 Table 8.2 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019 Table 8.3 Alpha-glucosidase Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025 Table 8.4 Glucobay: Revenue Forecast ($bn), 2014-2025 Table 8.5 Basen: Revenue Forecast ($bn), 2014-2025 Table 8.6 Glyset: Revenue Forecast ($bn), 2014-2025 Table 9.1 Meglitinides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014 Table 9.2 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019 Table 9.3 Meglitinides: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025 Table 9.4 Prandin: Revenue Forecast ($bn), 2014-2025 Table 9.5 Sarlix: Revenue Forecast ($bn), 2014-2025 Table 9.6 Glufast: Revenue Forecast ($bn), 2014-2025 Table 10.1 Thiazolidinediones: Revenues ($bn), 2014 Table 11.1 SGLT2 Inhibitors: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014 Table 11.2 SGLT2 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019 Table 11.3 SGLT2 Inhibitors: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025 Table 11.4 Invokana: Revenue Forecast ($bn), 2014-2025 Table 11.5 Forxiga: Revenue Forecast ($bn), 2014-2025 Table 11.6 Jardiance: Revenue Forecast ($bn), 2014-2025 Table 12.1 Biguanides: Revenues ($bn) and Market Shares (%) for Leading Drugs, 2014 Table 12.2 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2014-2019 Table 12.3 Biguanides: Revenue Forecasts ($bn) for Leading Drugs, 2020-2025 Table 12.4 Glucophage: Revenue Forecast ($bn), 2014-2025 Table 12.5 Glumetza: Revenue Forecast ($bn), 2014-2025 Table 12.6 Fortamet: Revenue Forecast ($bn), 2014-2025 Table 13.1 The Global Diabetes Drugs Market: Revenues ($bn) and Market Shares (%) by Region, 2014 Table 13.2 Leading National Diabetes Drugs Markets: Revenue Forecasts ($bn) by Region, 2014-2019 Table 13.3 Leading National Diabetes Drugs Markets: Revenue Forecasts ($bn) by Region, 2020-2025 Table 13.4 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025 Table 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025 Table 13.6 EU5 (Germany, France, UK, Italy, Spain) Market: Revenue ($bn) and Market Share (%) by Country, 2014 Table 13.7 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts ($bn), 2014-2019 Table 13.8 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($bn), 2020-2025 Table 13.9 Germany: Revenue Forecast ($bn), 2014-2025 Table 13.10 France: Revenue Forecast ($bn), 2014-2025 Table 13.11 Spain: Revenue Forecast ($bn), 2014-2025 Table 13.12 United Kingdom: Revenue Forecast ($bn), 2014-2025 Table 13.13 Italy: Revenue Forecast ($bn), 2014-2025 Table 13.14 China: Revenue Forecast ($bn), 2014-2025 Table 13.15 India: Revenue Forecast ($bn), 2014-2025 Table 13.16 Russia: Revenue Forecast ($bn), 2014-2025 Table 13.17 Brazil: Revenue Forecast ($bn), 2014-2025 Table 14.1 FDA Approved Anti Diabetes Drugs, 2014 Table 14.2 Expected FDA Approvals for Anti Diabetes Drugs, 2015 and 2016 Table 17.1 The Global Diabetes Drugs Market: Overall Revenue Forecast ($bn), 2014, 2016, 2019, 2022 and 2025 Table 17.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) and Market Shares (%) in Leading Regional Markets, 2014, 2019 and 2025 Table 17.3 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) In Leading Regional Markets, 2014, 2016, 2019, 2022 and 2025
List of Figures Figure 2.1 Diabetes Drugs Market Segmentation Overview, 2015 Figure 2.2 Diabetes Drugs Sub-market Segmentation, 2015 Figure 2.3 Diabetes Types and Classification, 2015 Figure 2.4 Diabetes Causes, 2015 Figure 2.5 Diabetes Regional Prevalence (population million), 2014 Figure 2.6 Diabetes Prevalence and Undetected Prevalence (%) by Region, 2014 Figure 2.7 World Number of Diabetics (population million), 2014-2025 Figure 3.1 World Diabetes Drugs Market: Market Share (%) by type of Medication, 2014 Figure 3.2 World Diabetes Drugs Market: Market Shares (%) by Drug Class, 2014 Figure 3.3 Top 10 Diabetes Drugs by Market Share (%), 2014 Figure 3.4 Top 10 Diabetes Drugs Producers vs Other Manufacturers: Market Share (%), 2014 Figure 3.5 Top 10 Diabetes Drugs Producers: Market Share (%), 2014 Figure 3.6 World Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2015 Figure 4.1 Human Insulins and Analogues: Market Shares (%) for Leading Drugs, 2014 Figure 4.2 Human Insulins and Analogues: Revenue Forecast ($bn), 2014-2025 Figure 4.3 Lantus: Drug Revenue Forecast ($bn), 2014-2025 Figure 4.4 NovoLog: Drug Revenue Forecast ($bn), 2014-2025 Figure 4.5 Humalog: Drug Revenue Forecast ($bn), 2014-2025 Figure 4.6 Levemir: Drug Revenue Forecast ($bn), 2014-2025 Figure 4.7 Human Insulins Novo: Drug Revenue Forecast ($bn), 2014-2025 Figure 4.8 NovoMix: Drug Revenue Forecast ($bn), 2014-2025 Figure 4.9 Humulin: Drug Revenue Forecast ($bn), 2014-2025 Figure 5.1 DPP-4 Inhibitors: Market Shares (%) for Leading Drugs, 2014 Figure 5.2 DPP-4 Inhibitors: Sales ($bn) for Leading Drugs, 2014 Figure 5.3 DPP-4 Inhibitors: Revenue Forecast ($bn), 2014-2025 Figure 5.4 Januvia: Revenue Forecast ($bn), 2014-2025 Figure 5.5 Janumet: Revenue Forecast ($bn), 2014-2025 Figure 5.6 Galvus: Revenue Forecast ($bn), 2014-2025 Figure 5.7 Onglyza: Revenue Forecast ($bn), 2014-2025 Figure 5.8 Nesina: Revenue Forecast ($bn), 2014-2025 Figure 5.9 Tradjenta: Revenue Forecast ($bn), 2014-2025 Figure 6.1 Sulfonylureas: Market Shares (%) for Leading Drugs, 2014 Figure 6.2 Sulfonylureas: Sales ($bn) for Leading Drugs, 2014 Figure 6.3 Sulfonylureas: Revenue Forecast ($bn), 2014-2025 Figure 6.4 Diamicron: Revenue Forecast ($bn), 2014-2025 Figure 6.5 Amaryl: Revenue Forecast ($bn), 2014-2025 Figure 6.6 Glucotrol: Revenue Forecast ($bn), 2014-2025 Figure 7.1 GLP-1: Market Shares (%) for Leading Drugs, 2014 Figure 7.2 GLP-1: Sales ($bn) for Leading Drugs, 2014 Figure 7.3 GLP-1 Receptor Agonists: Revenue Forecast ($bn), 2014-2025 Figure 7.4 Victoza: Revenue Forecast ($bn), 2014-2025 Figure 7.5 Byetta: Revenue Forecast ($bn), 2014-2025 Figure 7.6 Bydureon: Revenue Forecast ($bn), 2014-2025 Figure 8.1 Alpha-glucosidase Inhibitors: Revenue Sales ($bn), 2014 Figure 8.2 Alpha-glucosidase Inhibitors: Market Shares (%) for Leading Drugs, 2014 Figure 8.3 Alpha-glucosidase Inhibitors: Revenue Forecast ($bn), 2014-2025 Figure 8.4 Glucobay: Revenue Forecast ($bn), 2014-2025 Figure 8.5 Basen: Revenue Forecast ($bn), 2014-2025 Figure 8.6 Glyset: Revenue Forecast ($bn), 2014-2025 Figure 9.1 Meglitinides: Market Shares (%) for Leading Drugs, 2014 Figure 9.2 Meglitinides: Market Sales ($bn) for Leading Drugs, 2014 Figure 9.3 Meglitinides: Revenue Forecast ($bn), 2014-2025 Figure 9.4 Prandin: Revenue Forecast ($bn), 2014-2025 Figure 9.5 Sarlix: Revenue Forecast ($bn), 2014-2025 Figure 9.6 Glufast: Revenue Forecast ($bn), 2014-2025 Figure 10.1 Thiazolidinediones: Sales ($bn), 2014 Figure 11.1 SGLT2 Inhibitors: Sales ($bn) for Leading Drugs, 2014 Figure 11.2 SGLT2 Inhibitors: Market Share (%) for Leading Drugs, 2014 Figure 11.3 SGLT2 Inhibitors: Revenue Forecast ($bn), 2014-2025 Figure 11.4 Invokana: Revenue Forecast ($bn), 2014-2025 Figure 11.5 Forxiga: Revenue Forecast ($bn), 2014-2025 Figure 11.6 Jardiance: Revenue Forecast ($bn), 2014-2025 Figure 12.1 Biguanides: Market Shares (%) for Leading Drugs, 2014 Figure 12.2 Biguanides: Sales ($bn) for Leading Drugs, 2014 Figure 12.3 Biguanides: Revenue Forecast ($bn), 2014-2025 Figure 12.4 Glucophage: Revenue Forecast ($bn), 2014-2025 Figure 12.5 Glumetza: Revenue Forecast ($bn), 2014-2025 Figure 12.6 Fortamet: Revenue Forecast ($bn), 2014-2025 Figure 13.1 The Global Diabetes Drugs Market: Revenues ($bn) by Region, 2014 Figure 13.2 Top 3 Global Markets vs BRIC Countries: Market Shares (%), 2014 Figure 13.3 The Global Diabetes Drugs Market: Market Shares (%) by Region, 2014 Figure 13.4 The US Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025 Figure 13.5 The Japanese Diabetes Drugs Market: Revenue Forecast ($bn), 2014-2025 Figure 13.6 EU5 (Germany, France, UK, Italy, Spain) Countries: Revenue ($bn) by Country, 2014 Figure 13.7 EU5 (Germany, France, UK, Italy, Spain) Countries: Market Shares (%) by Country, 2014 Figure 13.8 EU5 (Germany, France, UK, Italy, Spain) Countries Market Global and EU5 Market Share (%), 2014 Figure 13.9 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecast ($bn), 2014-2025 Figure 13.10 EU5 (Germany, France, UK, Italy, Spain): Revenue Forecasts by Country ($bn), 2014-2025 Figure 13.11 Germany: Revenue Forecast ($bn), 2014-2025 Figure 13.12 France: Revenue Forecast ($bn), 2014-2025 Figure 13.13 Spain: Revenue Forecast ($bn), 2014-2025 Figure 13.14 United Kingdom: Revenue Forecast ($bn), 2014-2025 Figure 13.15 Italy: Revenue Forecast ($bn), 2014-2025 Figure 13.16 China: Revenue Forecast ($bn), 2014-2025 Figure 13.17 India: Revenue Forecast ($bn), 2014-2025 Figure 13.18 Russia: Revenue Forecast ($bn), 2014-2025 Figure 13.19 Brazil: Revenue Forecast ($bn), 2014-2025 Figure 15.1 SWOT Analysis of the World Diabetes Drugs Market, 2015-2025 Figure 15.2 STEP Analysis of the World Diabetes Drugs Market, 2015-2025 Figure 17.1 The Global Diabetes Drugs Market: Revenue Forecast ($bn), 2014, 2016, 2019, 2022 and 2025 Figure 17.2 The Global Diabetes Drugs Market: Revenue Forecasts ($bn) In Leading Regional Markets, 2014, 2016, 2019, 2022 and 2025
Actavis Alphapharm American Diabetes Association Amylin Pharmaceuticals (acquired by Bristol Myers Squibb) Andromeda Biotech Arisaph Associacao Nacional de Assistencia ao Diabetico (ANAD, Brazil) Astellas Pharma AstraZeneca Bayer Biocon Blue Cross Bristol-Myers Squibb Biogen Idec Boehringer Ingelheim Boston Therapeutics Chugai Pharmaceutical Diabetes UK DiaMedica Diamyd Medical Eisai Eli Lilly European Medicines Agency (EMA) Express Scripts Food and Drug Administration (US FDA) Franco-Indian Pharmaceuticals Furiex Pharmaceuticals Genentech Generex Biotechnology Corporation GlaxoSmithKline (GSK) Glenmark Pharmaceuticals Google Human Genome Sciences Intarcia International Diabetes Federation (IDF) Janssen (subsidiary of J&J) Johnson & Johnson (J&J) Lupin Kissei Pharmaceuticals Kotobuki Pharma Kowa MannKind Corporation Mascot Health Series Merck & Co. Merck Serono Ministry of Health (MoH, Germany) Ministry of Health, Labour and Welfare (MHLW, Japan) MSD KK (Asian subsidiary of Merck & Co.) Mylan National Health Service (NHS, UK) National Institute of Health and Clinical Excellence (NICE, UK) Novartis Novo Nordisk Ono Pharmaceuticals Oramed Pharmaceuticals Patheon Pfizer Ranbaxy Laboratories Roche Salix Pharmaceuticals Sandoz Sanofi Santarus (bought by Salix Pharmaceuticals) Servier Shantha Biotechnics (acquired by Sanofi) Shionogi Pharmaceuticals Shreya Life Sciences Stanford University School of Medicine Sun Pharma Takeda Taisho Pharmaceutical Teva Pharmaceutical Industries Transdermal Specialities United States Diabetes Prevention Program (DPP) World Health Organization (WHO) Yabao Pharmaceutical Zydus Cadila
Download sample pages
Complete the form below to download your free sample pages for Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025
Download sample pages
Complete the form below to download your free sample pages for Diabetes Drugs: World Industry, Market, R&D and Sales Forecasts 2015-2025
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
